Page 125 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVAXIN: Bharat Biotech Again Applies For Emergency Use Approval Of Its Covid-19 Vaccine Candidate

COVAXIN: Bharat Biotech Again Applies For Emergency Use Approval Of Its Covid-19 Vaccine Candidate Bharat Biotech s COVAXIN, Indiaâs first indigenous vaccine against Coronavirus. (Swarajya Magazine) Hyderabad-based Bharat Biotech, which is developing the country s indigenous coronavirus vaccine in collaboration with the Indian Council of Medical Research, on Wednesday (23 December) again applied to the Drug Controller General of India for the emergency use authorisation. The company applied for the emergency use authorisation in the evening, a company source told IANS. Emergency Use Authorisation is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies.

United statesUnited kingdomIndian council of medical researchSerum institute of indiaCentral drugs standard control organisationHyderabad based bharat biotechIndian councilMedical researchDrug controller generalUse authorisationSerum instituteBharat biotechஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிசீரம் நிறுவனம் ஆஃப் இந்தியா

Bharat Biotech Ocugen to co develop Covaxin for United States market-ANI

Hyderabad (Telangana) [India], December 22 (ANI): Hyderabad-based Bharat Biotech and US-based biopharmaceutical firm Ocugen Inc on Tuesday announced that they have signed a binding letter of intent (LOI) to co-develop the Indian firm s COVID-19 vaccine candidate Covaxin for the United States market. As per the letter of intent (LOI), Ocugen will have US rights to the vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical development, registration, and commercialisation for the US market. In a joint statement, the companies said that they have begun collaborating and will finalise details of the definitive agreement in the next few weeks. This collaboration leverages Ocugen s vaccine expertise, and its R&D and regulatory capabilities in the US.

United statesShankar musunuriKrishna ellaOcugen inc onHyderabad based bharat biotechOcugen incBharat biotechVaccine scientific advisory boardBiotech chairmanஒன்றுபட்டது மாநிலங்களில்கிருஷ்ணா எல்லாஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்பாரத் பயோடெக்பயோடெக் தலைவர்

Bharat Biotech again applies for vaccine s emergency approval

Bharat Biotech again applies for vaccine s emergency approval
daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNew delhiIndian council of medical researchSerum institute of indiaCentral drugs standard control organisationHyderabad based bharat biotechIndian councilMedical researchDrug controller generalUse authorisationSerum instituteBharat biotechஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்புதியது டெல்ஹி

Bharat Biotech to submit additional data for vaccine s emergency approval

Bharat Biotech to submit additional data for vaccine s emergency approval
daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNew delhiIndian council of medical researchCentral drugs standard control organizationSerum institute of indiaRegulatory agencyHyderabad based bharat biotechIndian councilMedical researchDrug controller generalSerum institutePune based serum instituteஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்புதியது டெல்ஹி

Coronavirus outbreak: Bharat Biotech s Covaxin generates dual immune response

India’s homegrown candidate vaccine against the novel coronavirus disease developed by the Hyderabad-based Bharat Biotech has generated a dual immune response that has raised hopes of immunity lasting six to 12 months. The candidate vaccine named Covaxin generated anti-coronavirus antibodies and stirred immune memory cells in the vaccinated volunteers, researchers with Bharat Biotech and the Indian Council of Medical Research said in a scientific paper released on Wednesday. The paper, describing the results of safety and immunogenicity trials in 380 volunteers in nine hospitals across the country, has also reported similar immune responses across age groups. The trials offered the candidate vaccine to volunteers aged between 12 years up to 65 years.

University of pennsylvaniaUnited statesNew delhiShankar musunuriTanmay majumdarKrishna ellaHarvey rubinNational institute of virologyNational institute of immunologyIndian council of medical researchOcugen incSerum institute of indiaHyderabad based bharat biotechBharat biotechIndian councilMedical research